Cited by

• Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.

  Schubiner H. Schubiner H. CNS Drugs. 2005;19(8):643-55. doi: 10.2165/00023210-200519080-00001. CNS Drugs. 2005. PMID: 16097847 Review.
• Multidimensional family therapy: addressing co-occurring substance abuse and other problems among adolescents with comprehensive family-based treatment.

  Rowe CL. Rowe CL. Child Adolesc Psychiatr Clin N Am. 2010 Jul;19(3):563-76. doi: 10.1016/j.chc.2010.03.008. Child Adolesc Psychiatr Clin N Am. 2010. PMID: 20682221 Free PMC article. Review.
• Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.

  Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W; SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Wolraich ML, et al. Pediatrics. 2019 Oct;144(4):e20192528. doi: 10.1542/peds.2019-2528. Pediatrics. 2019. PMID: 31570648 Free PMC article.
• Substance-use disorders in adolescents and adults with ADHD: focus on treatment.

  Wilens TE, Morrison NR. Wilens TE, et al. Neuropsychiatry (London). 2012 Aug;2(4):301-312. doi: 10.2217/npy.12.39. Neuropsychiatry (London). 2012. PMID: 23105949 Free PMC article.
• ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

  Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management; Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S. Subcommittee on Attention-Deficit/Hyperactivity Disorder, et al. Pediatrics. 2011 Nov;128(5):1007-22. doi: 10.1542/peds.2011-2654. Epub 2011 Oct 16. Pediatrics. 2011. PMID: 22003063 Free PMC article.